by scv-company | Jan 20, 2022 | News
Congratulate our CEO, Prof. Dr. Rösch, on his excellent “Pioneer lecture” about radionuclides in molecular imaging & therapy in the 35th International Austrian Winter Symposium 2022. In this congress Prof. Dr. Rösch presented how he developed the patented...
by scv-company | Jan 17, 2022 | News
The first comprehensive clinical trial around the world with our68Ga- and 177Lu-labeled theranostics pharmaceuticals based on homodimer FAP inhibitors is successfully published in Jan. 2022. In this trial 15 radioiodine-refractory differentiated thyroid cancer...
